

272 165

AMENDMENT TRANSMITTAL LETTER (Large Entity)


Applicant(s): K. Bortlik et al.

Docket No.

112701-593

| | | | | | |
|-------------------------------|-------------------------|------------------------|-----------------------|------------------------|--------------------------|
| Application No. 10/057,660 | Filing Date 01/25/02 | Examiner R.A. David | Customer No. 29157 | Group Art Unit 1651 | Confirmation No. 4348 |
|-------------------------------|-------------------------|------------------------|-----------------------|------------------------|--------------------------|

Invention: PRIMARY COMPOSITION COMPRISING A LIPOPHILIC BIOACTIVE COMPOUND



COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

| | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST # PREV. PAID FOR | NUMBER EXTRA CLAIMS PRESENT | RATE | ADDITIONAL FEE |
|--|-------------------------------------|-----------------------------|--------------------------------|------------|-------------------|
| TOTAL CLAIMS | 28 - | 28 = | 0 | x \$50.00 | \$0.00 |
| INDEP. CLAIMS | 2 - | 3 = | 0 | x \$200.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT | | | | | \$0.00 |

- No additional fee is required for amendment.
- Please charge Deposit Account No. in the amount of
- A check in the amount of to cover the filing fee is enclosed.
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 02-1818
 - Any additional filing fees required under 37 C.F.R. 1.16.
 - Any patent application processing fees under 37 CFR 1.17.
- Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Dated: June 13, 2005

Signature

Robert M. Barrett (Reg. No. 30,142)
 Bell, Boyd & Lloyd LLC
 P.O. Box 1135
 Chicago, Illinois 60690-1135
 Tel: 312/807-4204
 Fax: 312/827-8185

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

06/13/05

(Date)

Signature of Person Mailing Correspondence

Heather Foster

Typed or Printed Name of Person Mailing Correspondence

CC:

JUN 15 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): K. Bortlik et al.

Appl. No.: 10/057,660

Conf. No.: 4348

Filed: January 25, 2002

Title: PRIMARY COMPOSITION COMPRISING A LIOPHILIC BIOACTIVE
COMPOUND

Art Unit: 1651

Examiner: R.A. David

Docket No.: 112701-593

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the non-final Office Action dated March 22, 2005, please amend the above-identified patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 6 of this paper.